（文章来源：证券日报） 证券日报网讯 12月19日，东富龙发布公告称，公司第六届董事会第二十次（临时）会议审议通过《关 于部分募投项目延期的议案》。 ...

Group 1 - Dongfulong (SZ 300171) announced on December 19 that its 20th temporary board meeting of the sixth session was held via communication voting, discussing the proposal for the postponement of certain fundraising projects [1] - For the year 2024, Dongfulong's revenue composition is as follows: specialized equipment manufacturing accounts for 99.84%, while services account for 0.16% [1] - As of the report, Dongfulong's market capitalization is 11.8 billion yuan [1]

第六届董事会第二十次（临时）会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 证券代码：300171 证券简称：东富龙 公告编号：2025-038 东富龙科技集团股份有限公司 经审议，董事会同意：公司结合当前募投项目实际进展情况，将"生物制药 装备产业试制中心项目"达到预定可使用状态的日期由 2026 年 3 月 24 日延期至 2027 年 3 月 24 日，将"江苏生物医药装备产业化基地项目"达到预定可使用状 态的日期由 2026 年 1 月 10 日延期至 2027 年 1 月 10 日，将"浙江东富龙生物技 术有限公司生命科学产业化基地项目"达到预定可使用状态的日期由 2026 年 7 月 15 日延期至 2027 年 7 月 15 日。公司本次部分募投项目的延期，未改变项目 实施主体、实施方式、募集资金用途及投资规模，不存在变相改变募集资金投向 和损害其他股东利益的情形，不会对公司正常经营产生不利影响，符合公司长期 发展规划。 投票结果：赞成票，9 票，占出席会议董事的 100%；反对票，0 票，占出席 会议董事的 0%；弃权票，0 票 ...

中信证券股份有限公司关于 东富龙科技集团股份有限公司 部分募投项目延期的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为东富龙科 技集团股份有限公司（以下简称"东富龙"或"公司"）2022年度向特定对象发行A股 股票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上 市公司规范运作》《上市公司募集资金监管规则》等有关规定，对东富龙部分募 投项目延期的事项进行了核查，核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会于2022年10月8日出具的《关于同意东富龙科技集 团股份有限公司向特定对象发行股票注册的批复》（证监许可[2022]2372号）核准， 公司向特定对象发行人民币普通股（A股）120,000,000股，每股面值人民币1.00 元，发行价格为人民币20.57元/股，募集资金总额为2,468,400,000.00元，扣除与 募集资金相关的发行费用40,086,534.56元（不含税金额），实际募集资金净额为 2,428,313,465.44元。 （二）募投项目延期的原因 上述募集 ...

证券代码：300171 证券简称：东富龙 公告编号：2025-039 东富龙科技集团股份有限公司 关于部分募投项目延期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 东富龙科技集团股份有限公司（以下简称"公司"）于2025年12月19日召开 第六届董事会第二十次（临时）会议，审议通过了《关于部分募投项目延期的议 案》，同意公司结合当前募投项目实际进展情况，在募投项目实施主体、实施方 式、募集资金用途及投资规模不发生变更的情况下，将"生物制药装备产业试制 中心项目"达到预定可使用状态的日期由2026年3月24日延期至2027年3月24日， 将"江苏生物医药装备产业化基地项目"达到预定可使用状态的日期由2026年1 月10日延期至2027年1月10日，将"浙江东富龙生物技术有限公司生命科学产业 化基地项目"达到预定可使用状态的日期由2026年7月15日延期至2027年7月15 日。上述事项不涉及募集资金用途变更，无需提交公司股东会审议。公司保荐机 构中信证券股份有限公司对本事项出具了无异议的核查意见。现将相关情况公告 如下： 一、募集资金的基本情况 经中 ...

Core Viewpoint - The company emphasizes its commitment to information disclosure and reports significant growth in international business revenue, alongside a focus on technological innovation and strategic growth opportunities [1] Group 1: Financial Performance - In the first half of 2025, the company achieved international business revenue of 805 million yuan, accounting for 33.14% of total revenue, representing a year-on-year growth of 63.25% [1] Group 2: Strategic Focus - The company is committed to technological innovation and plans to increase investment in research and development, focusing on key technologies and processes in the pharmaceutical and equipment industries [1] - The company aims to continuously develop new products and improve existing ones to create a portfolio of core competitive products [1] Group 3: Growth Opportunities - The company will actively seek new external growth opportunities, considering business layout, synergy effects, innovation, and uniqueness, to achieve a coordinated development of both internal and external growth [1]

证券日报网讯 12月3日，东富龙在互动平台回答投资者提问时表示，公司在定期报告中披露股东总数。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Vison Pharmaceutical-B (02561), which rose over 12% and is currently trading at 35.26 HKD with a transaction volume of 1.9082 million HKD [1] - Anke Bio recently disclosed progress in its collaboration with Vison Pharmaceutical, indicating that the growth-promoting factor, Longpei, is about to receive approval [1] - On November 6, during the 8th China International Import Expo, Vison Pharmaceutical established a strategic cooperation on dual-chamber freeze-drying technology with Dongfulong, a leading domestic pharmaceutical equipment company, and signed an industrial collaboration agreement with the Lingang New Area Management Committee and Lingang Group's trade platform, further implementing its strategy of "Global Innovation, China Acceleration" [1]

Core Viewpoint - Vison Pharmaceutical-B (02561) has seen a significant stock increase of over 12%, currently trading at 35.26 HKD with a transaction volume of 1.9082 million HKD, driven by recent collaboration announcements and strategic partnerships [1] Group 1: Company Developments - Anke Bio recently disclosed progress in its collaboration with Vison Pharmaceutical, indicating that the growth-promoting agent Longpei is nearing approval [1] - On November 6, during the 8th China International Import Expo, Vison Pharmaceutical established a strategic cooperation on dual-chamber freeze-drying technology with leading domestic pharmaceutical equipment company Dongfulong [1] - Vison Pharmaceutical signed an industrial collaboration agreement with the Lingang New Area Management Committee and Lingang Group's trade platform, further advancing its strategy of "Global Innovation, China Acceleration" [1]

Group 1 - The core viewpoint of the news is that Dongfulong's stock has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 25.62% [1] - As of November 20, Dongfulong's stock price is 16.55 yuan per share, with a market capitalization of 12.674 billion yuan [1] - The company has seen a net outflow of 8.8464 million yuan in principal funds, with significant selling pressure from large orders [1] Group 2 - For the period from January to September 2025, Dongfulong achieved operating revenue of 3.704 billion yuan, representing a year-on-year growth of 6.14%, while net profit attributable to shareholders decreased by 13.86% to 132 million yuan [2] - The number of shareholders as of September 30, 2025, is 31,400, a decrease of 2.14% from the previous period, with an average of 17,910 circulating shares per person, an increase of 2.19% [2] - Dongfulong has distributed a total of 1.782 billion yuan in dividends since its A-share listing, with 512 million yuan distributed over the past three years [3]